RU2017145692A - Композиции никотинамида рибозида и птеростильбена и способы лечения заболеваний кожи - Google Patents
Композиции никотинамида рибозида и птеростильбена и способы лечения заболеваний кожи Download PDFInfo
- Publication number
- RU2017145692A RU2017145692A RU2017145692A RU2017145692A RU2017145692A RU 2017145692 A RU2017145692 A RU 2017145692A RU 2017145692 A RU2017145692 A RU 2017145692A RU 2017145692 A RU2017145692 A RU 2017145692A RU 2017145692 A RU2017145692 A RU 2017145692A
- Authority
- RU
- Russia
- Prior art keywords
- effective amount
- therapeutically effective
- per day
- composition according
- nicotinamide riboside
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 17
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 title claims 9
- 235000020956 nicotinamide riboside Nutrition 0.000 title claims 9
- 239000011618 nicotinamide riboside Substances 0.000 title claims 9
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000017520 skin disease Diseases 0.000 claims 10
- 201000004624 Dermatitis Diseases 0.000 claims 6
- 208000010668 atopic eczema Diseases 0.000 claims 6
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims 6
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 206010041955 Stasis dermatitis Diseases 0.000 claims 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010047642 Vitiligo Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 206010058130 Asteatosis Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 2
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 2
- 206010014970 Ephelides Diseases 0.000 claims 2
- 206010053177 Epidermolysis Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 2
- 108010010803 Gelatin Proteins 0.000 claims 2
- 206010064000 Lichenoid keratosis Diseases 0.000 claims 2
- 208000003351 Melanosis Diseases 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 206010051246 Photodermatosis Diseases 0.000 claims 2
- 206010034972 Photosensitivity reaction Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 2
- 206010039796 Seborrhoeic keratosis Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010064127 Solar lentigo Diseases 0.000 claims 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 2
- 206010042496 Sunburn Diseases 0.000 claims 2
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims 2
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims 2
- 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 208000009621 actinic keratosis Diseases 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 235000012745 brilliant blue FCF Nutrition 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- 239000007766 cera flava Substances 0.000 claims 2
- ONTQJDKFANPPKK-UHFFFAOYSA-L chembl3185981 Chemical compound [Na+].[Na+].CC1=CC(C)=C(S([O-])(=O)=O)C=C1N=NC1=CC(S([O-])(=O)=O)=C(C=CC=C2)C2=C1O ONTQJDKFANPPKK-UHFFFAOYSA-L 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 208000024386 fungal infectious disease Diseases 0.000 claims 2
- 229940084434 fungoid Drugs 0.000 claims 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 2
- 229920000159 gelatin Polymers 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000019322 gelatine Nutrition 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 229960003943 hypromellose Drugs 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000004006 olive oil Substances 0.000 claims 2
- 235000008390 olive oil Nutrition 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 230000036211 photosensitivity Effects 0.000 claims 2
- 208000017983 photosensitivity disease Diseases 0.000 claims 2
- 239000008213 purified water Substances 0.000 claims 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 2
- 201000003385 seborrheic keratosis Diseases 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- -1 sunflower lecithin Chemical compound 0.000 claims 2
- 229940005741 sunflower lecithin Drugs 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 239000004408 titanium dioxide Substances 0.000 claims 2
- 235000013311 vegetables Nutrition 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 230000037303 wrinkles Effects 0.000 claims 2
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 230000001175 peptic effect Effects 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 230000036561 sun exposure Effects 0.000 claims 1
- 235000010215 titanium dioxide Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173733P | 2015-06-10 | 2015-06-10 | |
| US62/173,733 | 2015-06-10 | ||
| PCT/US2016/019653 WO2016200447A1 (en) | 2015-06-10 | 2016-02-25 | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017145692A true RU2017145692A (ru) | 2019-07-10 |
| RU2017145692A3 RU2017145692A3 (enExample) | 2019-07-31 |
Family
ID=57503873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017145692A RU2017145692A (ru) | 2015-06-10 | 2016-02-25 | Композиции никотинамида рибозида и птеростильбена и способы лечения заболеваний кожи |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11426398B2 (enExample) |
| EP (1) | EP3307754B1 (enExample) |
| JP (1) | JP2018517774A (enExample) |
| KR (1) | KR20180021784A (enExample) |
| CN (1) | CN107849083A (enExample) |
| AU (2) | AU2016274126A1 (enExample) |
| CA (1) | CA2989115C (enExample) |
| ES (1) | ES2932801T3 (enExample) |
| MX (2) | MX389207B (enExample) |
| RU (1) | RU2017145692A (enExample) |
| TW (1) | TWI725033B (enExample) |
| WO (1) | WO2016200447A1 (enExample) |
| ZA (1) | ZA201800056B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016274126A1 (en) | 2015-06-10 | 2018-01-18 | Elysium Health, Inc. | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
| US20180325931A1 (en) | 2017-01-21 | 2018-11-15 | Ningbo Zhiming Biotechnology Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
| ES3014265T3 (en) | 2017-03-17 | 2025-04-21 | Elysium Health Inc | Combination of nicotinamide riboside and pterostilbene for use in treating or preventing liver damage |
| JP2020517736A (ja) * | 2017-04-24 | 2020-06-18 | エリシウム ヘルス，インコーポレーテッド | 腎臓損傷の治療及び予防 |
| JP7143402B2 (ja) * | 2017-05-17 | 2022-09-28 | ウニベルシタ デ バレンシア－エストゥディ ヘネラル | ニコチンアミドリボシドを使用する運動ニューロン疾患の治療及び予防 |
| WO2018213715A1 (en) * | 2017-05-18 | 2018-11-22 | Elysium Health, Inc. | Methods and compositions for improving sleep |
| CN111542312A (zh) * | 2017-07-28 | 2020-08-14 | 老龄化控制中心股份公司 | 预防和逆转衰老方面的组合物和方法 |
| CN109589309A (zh) * | 2017-09-30 | 2019-04-09 | 浙江嘉华化工有限公司 | 烟酰胺核糖微囊的制备方法 |
| CN111601814A (zh) * | 2017-10-19 | 2020-08-28 | 益力舒健康公司 | Tdp-43相关疾病的预防和治疗 |
| US20210186996A1 (en) * | 2017-12-01 | 2021-06-24 | Elysium Health, Inc. | Methods and compositions for treating multiple sclerosis |
| WO2019108875A1 (en) * | 2017-12-01 | 2019-06-06 | Elysium Health, Inc. | Methods and compositions for treating glaucoma |
| GB201811312D0 (en) * | 2018-07-10 | 2018-08-29 | Nuchido Ltd | Compositions |
| SG11202102204PA (en) | 2018-09-25 | 2021-04-29 | Ponce De Leon Health Designated Activity Company | Process of making calcium alpha-ketoglutarate |
| CN111569084B (zh) * | 2019-02-19 | 2021-07-13 | 中国科学院上海药物研究所 | 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途 |
| WO2020176445A1 (en) * | 2019-02-26 | 2020-09-03 | Universitat De Valencia-Estudi General | Methods and compositions for treating motor neuron diseases |
| WO2020190703A1 (en) * | 2019-03-21 | 2020-09-24 | Elysium Health, Inc. | Methods for wound treatment |
| CN113768946A (zh) * | 2020-05-25 | 2021-12-10 | 南京帝昌医药科技有限公司 | 一种治疗糖尿病皮肤并发症的软膏及其制备方法 |
| CN113712193A (zh) * | 2020-05-25 | 2021-11-30 | 南京帝昌医药科技有限公司 | 修复皮肤系统的组合物制备方法及其用途 |
| US20230270770A1 (en) * | 2020-07-30 | 2023-08-31 | Moises HERNANDEZ-VAZQUEZ | Nutritional supplements for repairing muscle and defending against deterioration from human aging |
| EP4380577A1 (en) * | 2021-08-02 | 2024-06-12 | Nuvamid SA | Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ES2670927T3 (es) * | 2005-11-18 | 2018-06-04 | Cornell Research Foundation, Inc. | Composiciones de nicotinoil ribósido y métodos de uso |
| EP2322159A1 (en) | 2009-10-30 | 2011-05-18 | Green Molecular, S.L. | Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic |
| CN103547256A (zh) | 2011-03-23 | 2014-01-29 | 加利福尼亚大学校务委员会 | 炎性和传染性皮肤病的治疗 |
| US8841350B2 (en) | 2011-05-11 | 2014-09-23 | ChromaDex Inc. | Method for inducing UDP-glucuronosyltransferase activity using pterostilbene |
| US20130296440A1 (en) | 2012-05-01 | 2013-11-07 | ChromaDex Inc. | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation |
| CA2928656C (en) * | 2013-10-30 | 2020-07-28 | ChromaDex Inc. | Nicotinamide riboside compositions for topical use in treating skin conditions |
| CN106715455A (zh) * | 2014-06-06 | 2017-05-24 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 烟酰胺核苷类似物及其药物组合物和用途 |
| EP3271370B1 (en) | 2015-03-16 | 2023-06-21 | Chromadex Inc. | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof |
| US20180071273A1 (en) * | 2015-03-17 | 2018-03-15 | Speccialty Nutrition Group, Inc. | Nutritional compositions to enhance mitochondrial energy production |
| AU2016274126A1 (en) | 2015-06-10 | 2018-01-18 | Elysium Health, Inc. | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
-
2016
- 2016-02-25 AU AU2016274126A patent/AU2016274126A1/en not_active Abandoned
- 2016-02-25 WO PCT/US2016/019653 patent/WO2016200447A1/en not_active Ceased
- 2016-02-25 US US15/735,066 patent/US11426398B2/en active Active
- 2016-02-25 JP JP2018517123A patent/JP2018517774A/ja active Pending
- 2016-02-25 CN CN201680046668.7A patent/CN107849083A/zh active Pending
- 2016-02-25 EP EP16807940.8A patent/EP3307754B1/en active Active
- 2016-02-25 RU RU2017145692A patent/RU2017145692A/ru unknown
- 2016-02-25 ES ES16807940T patent/ES2932801T3/es active Active
- 2016-02-25 KR KR1020187000353A patent/KR20180021784A/ko not_active Ceased
- 2016-02-25 MX MX2017016024A patent/MX389207B/es unknown
- 2016-02-25 CA CA2989115A patent/CA2989115C/en active Active
- 2016-06-13 TW TW105118370A patent/TWI725033B/zh active
-
2017
- 2017-12-08 MX MX2021012600A patent/MX2021012600A/es unknown
-
2018
- 2018-01-04 ZA ZA2018/00056A patent/ZA201800056B/en unknown
-
2020
- 2020-12-08 AU AU2020286208A patent/AU2020286208B2/en active Active
-
2022
- 2022-07-25 US US17/872,575 patent/US12109206B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020286208A1 (en) | 2021-01-07 |
| AU2016274126A1 (en) | 2018-01-18 |
| CN107849083A (zh) | 2018-03-27 |
| EP3307754A1 (en) | 2018-04-18 |
| TW201713322A (zh) | 2017-04-16 |
| MX2021012600A (es) | 2021-11-12 |
| EP3307754B1 (en) | 2022-09-14 |
| CA2989115C (en) | 2024-01-02 |
| CA2989115A1 (en) | 2016-12-15 |
| US12109206B2 (en) | 2024-10-08 |
| RU2017145692A3 (enExample) | 2019-07-31 |
| MX2017016024A (es) | 2018-08-15 |
| KR20180021784A (ko) | 2018-03-05 |
| US20180353497A1 (en) | 2018-12-13 |
| EP3307754A4 (en) | 2019-03-27 |
| WO2016200447A1 (en) | 2016-12-15 |
| US11426398B2 (en) | 2022-08-30 |
| MX389207B (es) | 2025-03-20 |
| JP2018517774A (ja) | 2018-07-05 |
| TWI725033B (zh) | 2021-04-21 |
| US20220362233A1 (en) | 2022-11-17 |
| ZA201800056B (en) | 2023-10-25 |
| AU2020286208B2 (en) | 2022-11-10 |
| ES2932801T3 (es) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017145692A (ru) | Композиции никотинамида рибозида и птеростильбена и способы лечения заболеваний кожи | |
| JP2018517774A5 (enExample) | ||
| Asongalem et al. | Analgesic and antiinflammatory activities of Erigeron floribundus | |
| Guo et al. | Antinociceptive and anti-inflammatory activities of ethyl acetate fraction from Zanthoxylum armatum in mice | |
| KR102141081B1 (ko) | 항염증 또는 피부 미백용 조성물 | |
| HK1200716A1 (zh) | 使用胞苷類似物的口服製劑治療癌症的方法 | |
| JP2010506900A5 (enExample) | ||
| JP2018537513A5 (enExample) | ||
| EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
| KR20240052856A (ko) | 15-hepe를 포함하는 조성물 및 이를 사용하는 방법 | |
| AU2012212153A1 (en) | Bakuchiol compositions for treatment of post inflammatory hyperpigmentation | |
| RU2015103469A (ru) | Ретиноиды и их применение | |
| RU2020123900A (ru) | Новые соединения, ингибирующие mtor | |
| CA3191534A1 (en) | Senolytic compounds and compositions | |
| CN104519861A (zh) | 治疗皮肤炎症和相关综合征的化妆美容用和/或药用组合物 | |
| RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
| JP6422737B2 (ja) | ロキソプロフェンを配合する外用剤組成物 | |
| RU2011129815A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи | |
| JP2016501236A5 (enExample) | ||
| Park et al. | Protective effect of hexane extracts of Uncaria sinensis against photothrombotic ischemic injury in mice | |
| HRP20191256T1 (hr) | Pripravak koji sadrži melatonin ili njegove derivate uz koenzim q10, te njegova upotreba protiv starenja kože | |
| JP2008534527A (ja) | そう痒の治療および予防のためのオキサプロジンまたは密接に関連する化合物 | |
| BE1019432A3 (fr) | Utilisation d'isothiocyanates et derives pour le traitement et/ou la prevention des lucites. | |
| WO2007032010A3 (en) | Use of tellurium compounds for protection from ultra-violet radiation | |
| Jin et al. | Pharmacokinetics and safety of idelalisib, a novel PI3Kδ inhibitor, in Japanese and Caucasian subjects |